N4 Pharma Stock Price, News & Analysis (LON:N4P)

GBX 9.52 -0.23 (-2.36 %)
(As of 12/18/2017 03:48 AM ET)
Previous CloseGBX 9.75
Today's RangeGBX 9.52 - GBX 9.52
52-Week RangeGBX 4.88 - GBX 12.50
Volume10,000 shs
Average Volume649,630 shs
Market Capitalization£8.95 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About N4 Pharma (LON:N4P)

N4 Pharma logoN4 Pharma Plc, formerly Onzima Ventures plc, is a United Kingdom-based specialist pharmaceutical company. The Company is engaged in reformulating existing drugs and vaccines to improve their performance. It operates in two divisions: generic and vaccines. Its generics division includes Sildenafil, Sartans, Aprepitant and Single dose Hepatitis B. Its vaccines include Nuvac and Nuvec. The Company is improving Sildenafil for erectile dysfunction. Sartans is a family of drugs known as Angiotensin II antagonists, including Losartan and Valsartan, commonly used for the treatment of hypertension. Aprepitant is an anti-emetic drug used in oncology. It is reformulating the existing Hepatitis B surface antigen vaccine (HBsAg), a sub unit vaccine. Nuvac is a nano-carrier delivery system for vaccines. Nuvec is an engineered silica nanoparticle, which has been designed for the intracellular delivery of large nucleic acids such as plasmid deoxyribonucleic acid and messenger ribonucleic acid.

Receive N4P News and Ratings via Email

Sign-up to receive the latest news and ratings for N4P and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorPharmaceuticals - NEC
SymbolLON:N4P
CUSIPN/A
Phone+44-1332-690061

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net IncomeN/A
Net Margins1.05%
Return on Equity1.54%
Return on Assets1.46%

Miscellaneous

EmployeesN/A
Outstanding Shares74,710,000

N4 Pharma (LON:N4P) Frequently Asked Questions

What is N4 Pharma's stock symbol?

N4 Pharma trades on the London Stock Exchange (LON) under the ticker symbol "N4P."

Where is N4 Pharma's stock going? Where will N4 Pharma's stock price be in 2017?

1 brokers have issued 1 year price objectives for N4 Pharma's stock. Their predictions range from GBX 12 to GBX 12. On average, they anticipate N4 Pharma's share price to reach GBX 12 in the next year. View Analyst Ratings for N4 Pharma.

Who are some of N4 Pharma's key competitors?

Who are N4 Pharma's key executives?

N4 Pharma's management team includes the folowing people:

  • Nigel James Theobald, Chief Executive Officer, Executive Director
  • Paul Titley, Executive Director
  • David Templeton, Non-Executive Chairman of the Board
  • Luke Sebastian Cairns, Non-Executive Director (Age 38)

How do I buy N4 Pharma stock?

Shares of N4 Pharma and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is N4 Pharma's stock price today?

One share of N4 Pharma stock can currently be purchased for approximately GBX 9.52.

How big of a company is N4 Pharma?

N4 Pharma has a market capitalization of £8.95 million.

How can I contact N4 Pharma?

N4 Pharma's mailing address is Weston House, 1 Bradgate Park View, DERBY, DE73 5UJ, United Kingdom. The company can be reached via phone at +44-1332-690061.


MarketBeat Community Rating for N4 Pharma (N4P)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  23 (Vote Outperform)
Underperform Votes:  31 (Vote Underperform)
Total Votes:  54
MarketBeat's community ratings are surveys of what our community members think about N4 Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

N4 Pharma (LON:N4P) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldN/A
Consensus Rating Score: 2.002.002.00N/A
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: GBX 12GBX 12N/AN/A

N4 Pharma (LON:N4P) Consensus Price Target History

Price Target History for N4 Pharma (LON:N4P)

N4 Pharma (LON:N4P) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
11/30/2017Beaufort SecuritiesReiterated RatingSpeculative BuyGBX 12View Rating Details
(Data available from 12/18/2015 forward)

Earnings

Earnings History for N4 Pharma (LON:N4P)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

N4 Pharma (LON:N4P) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for N4 Pharma (LON:N4P)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

N4 Pharma (LON N4P) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for N4 Pharma (LON:N4P)

N4 Pharma (LON N4P) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/10/2017Nigel TheobaldInsiderBuy56,656GBX 8£4,532.48
(Data available from 1/1/2013 forward)

Headlines

N4 Pharma (LON N4P) News Headlines

Source:
DateHeadline
Beaufort Securities Reiterates "Speculative Buy" Rating for N4 Pharma (N4P)Beaufort Securities Reiterates "Speculative Buy" Rating for N4 Pharma (N4P)
www.americanbankingnews.com - November 30 at 11:02 PM
N4 Pharma Plc (N4P) Insider Buys £4,532.48 in StockN4 Pharma Plc (N4P) Insider Buys £4,532.48 in Stock
www.americanbankingnews.com - November 10 at 12:38 PM
N4 Pharma PLC (N4P) Posts  Earnings ResultsN4 Pharma PLC (N4P) Posts Earnings Results
www.americanbankingnews.com - September 25 at 7:22 AM
N4 Pharma PLC (N4P) Rating Reiterated by Beaufort SecuritiesN4 Pharma PLC (N4P) Rating Reiterated by Beaufort Securities
www.americanbankingnews.com - July 3 at 6:34 AM

SEC Filings

N4 Pharma (LON:N4P) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

N4 Pharma (LON N4P) Stock Chart for Monday, December, 18, 2017

Loading chart…

This page was last updated on 12/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.